Unknown PHASE3 INTERVENTIONAL 4-arm NCT00499018

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma (DLCL04)

A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.

Sponsor: Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Conditions Diffuse Large B-Cell Lymphoma IPI≥2

Interventions ARA-C ASCT BCNU Ciclofosfamide Doxorubicina Lenograstim Mitoxantrone Pegfilgrastim Prednisone Rituximab VP-16 Vincristina

Updated 7 times since 2017 Last updated: Feb 14, 2011 Started: Jan 31, 2006 Primary completion: Jun 30, 2011 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diffuse Large B-Cell Lymphoma and IPI≥2, this trial is ongoing. The trial is conducted by Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jun 2023 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2021 — Jun 2023 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Fondazione Italiana Linfomi - ETS

Data source: Fondazione Italiana Linfomi - ETS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Asti, Italy , Aviano - PN, Italy , Bari, Italy , Biella, Italy , Bologna, Italy , Brescia, Italy , Brindisi, Italy , Busto Arsizio - VA, Italy , Cagliari, Italy and 51 more locations